SGLT2抑制剂肾脏结局试验参与者与真实世界CKD初级保健人群的比较
本研究利用英国初级保健数据库进行横断面分析,发现真实世界CKD人群中仅0.9%、2.2%和8.0%分别符合CREDENCE、DAPA-CKD和EMPA-KIDNEY的入选标准。所有试验均更代表合并2型糖尿病的患者,试验参与者比真实世界人群年轻9-14岁且CKD更严重。
要点
- 真实世界CKD患者中符合SGLT2抑制剂肾脏结局试验标准者比例很低。
- 试验人群更年轻、CKD更重、合并T2D比例更高,女性代表性不足。
- 需结合真实世界研究评估SGLT2抑制剂在广泛CKD人群中的有效性。
核心结论
- SGLT2抑制剂肾脏结局试验仅代表具有高肾脏不良事件风险的CKD亚组人群。
主要发现
- 真实世界CKD人群中符合CREDENCE、DAPA-CKD和EMPA-KIDNEY入选标准的比例分别为0.9%、2.2%和8.0%。
- 所有试验均更代表合并T2D的患者:CREDENCE、DAPA-CKD和EMPA-KIDNEY试验中T2D比例分别为100%、67.6%和44.5%,而真实世界CKD人群为32.8%。
- 试验参与者比真实世界CKD人群年轻9-14岁,且CKD更进展,包括白蛋白尿水平更高。
- 试验参与者几乎均使用肾素-血管紧张素系统抑制剂,而真实世界CKD人群使用率不足一半。
- 女性在试验中代表性不足且更不易符合入选标准。
临床怎么用
- 临床应认识到SGLT2抑制剂肾脏结局试验结果可能不直接适用于所有CKD患者。
- 在广泛CKD人群中应用SGLT2抑制剂时需结合真实世界证据评估疗效。
局限性
- 横断面分析设计无法确定因果关系。
- 研究基于英国初级保健数据,外推至其他医疗体系需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies suggest sodium-glucose co-transporter 2 (SGLT2) inhibitor kidney outcome trials are not representative of the broader population of people with chronic kidney disease (CKD). However, there are limited data on the generalizability to those without co-existing type 2 diabetes (T2D), and the representativeness of the Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) trial has not been adequately explored. We hypothesized that SGLT2 inhibitor kidney outcome trials are more representative of people with co-existing T2D than those without, and that EMPA-KIDNEY is more representative than previous trials. METHODS: A cross-sectional analysis of adults with CKD in English primary care was conducted using the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub. The proportions that met the eligibility criteria of SGLT2 inhibitor kidney outcome trials were determined, and their characteristics described. Logistic regression analyses were performed to identify factors associated with trial eligibility. RESULTS: Of 6 670 829 adults, 516 491 (7.7%) with CKD were identified. In the real-world CKD population, 0.9%, 2.2% and 8.0% met the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD) and EMPA-KIDNEY eligibility criteria, respectively. All trials were more representative of people with co-existing T2D than those without T2D. Trial participants were 9-14 years younger than the real-world CKD population, and had more advanced CKD, including higher levels of albuminuria. A higher proportion of the CREDENCE (100%), DAPA-CKD (67.6%) and EMPA-KIDNEY (44.5%) trial participants had T2D compared with the real-world CKD population (32.8%). Renin-angiotensin system inhibitors were prescribed in almost all trial participants, compared with less than half of the real-world CKD population. Females were under-represented and less likely to be eligible for the trials. CONCLUSION: SGLT2 inhibitor kidney outcome trials represent a subgroup of people with CKD at high risk of adverse kidney events. Our study highlights the importance of complementing trials with real-world studies, exploring the effectiveness of SGLT2 inhibitors in the broader population of people with CKD.
引用
- Forbes AK, Hinton W, Feher MD, et al. A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population. Nephrol Dial Transplant. 2024. PMID: 38520170. doi:10.1093/ndt/gfae071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。